ImmunoGrow

Project "ImmunoGrow" data sheet

The following table provides information about the project.

 Partnership

Take a look of project's partnership.

Map

 Project objective

Lifesaving cell-based CAR-T therapies have achieved remission rates of up to 83% for patients with the most aggressive and untreatable cancers. These therapies harness a patient’s own genetically engineered immune cells to target cancer cells. However, manufacturers are struggling to produce these individualised treatments at scale resulting in prohibitive prices as high as $475,000 per treatment. Unless solutions that address these limitations are provided, publically-funded EU healthcare systems & citizens will be priced out of these life-changing therapies.

The challenges they face include poor cell growth performance due to patient sample variability, limitations associated with equipment adopted from the research lab that require costly skilled labour, costly consumables and expensive cleanroom infrastructure.

Compared to the gold standard, Dynabeads, initial testing has shown that the ImmunoGrow technology produces an 8x higher cell yield which helps to save the sickest patients who have limited cells and significantly reduce the cost to manufacture these therapies by simplifying the process, reducing the requirement for skilled operator input and making this step both ‘closed’ and automated. ImmunoGrow achieves this through its patent-protected mesh structure that mimics the natural growth conditions cells encounter in the body.

Grey Matter Technologies (‘GMT’) Ltd. is seeking support to help fund trials with two identified customers as well to help it to conduct an independent set of tests on the product’s performance. Both these trials, as well as an associated business plan or feasibility study, will be core to the raising of a seed round of €500,000 in 2019 to further develop the technology with the release of a full-scale product anticipated for Q3 2021. GMT expects to capture 15% of the $600mn addressable T-Cell Activation market in 2030. In doing so, it will make these life changing treatments cheaper, safer and more widely available.